27th May 2025 07:00
27 May 2025
AOTI, INC. (the "Company" or "Group" or "AOTI")
2024 Annual Report and Notice of Annual General Meeting
AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable healing of wounds and the prevention of amputations, announces that electronic copies of the Company's Annual Report and Financial Statements for the year ended 31 December 2024, together with the 2025 Notice of Annual General Meeting (the 'Notice'), Form of Instruction and Proxy form swill shortly be available on the Company's website at:
https://aotinc.net/investors/financial-reports-publications-2/
The Annual General Meeting ('AGM') will be held at 10:00 British Summer Time (BST) on Wednesday, 25 June 2025 at Temple Chambers, 3 - 7 Temple Avenue, London, EC4Y 0DT, United Kingdom.
Shareholders are encouraged to vote on the resolutions to be put to the AGM by proxy whether or not they intend to attend. Voting by proxy prior to the AGM does not affect shareholders' right to attend the AGM and vote in person should they so wish. Holders of Depositary Interests will be sent a Form of Instruction for voting their shares and all other shareholders will be sent the Notice and Proxy form; with all items posted on or around 27 May 2025.
Full details of the operation and arrangements for the AGM are set out in the Notice.
ENDS
AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins, Alex Davis |
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net
Related Shares:
Aoti, Inc.